Radius Health Inc.
NASDAQ:RDUS
| Market Cap (Intraday) | 892.46M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | 21.62 |
| 10-Day MA | $18.80 |
| 50-Day MA | $20.07 |
| 200-Day MA | $17.72 |
Radius Health Inc. Stock, NASDAQ:RDUS
22 Boston Wharf Road, 7th floor, Boston, Massachusetts 02210
United States of America
Phone: +1.617.551.4000
Number of Employees: 310
Description
Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company�s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes abaloparatide transdermal patch for potential use in osteoporosis; and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Boston, MA.